Table 3.

Univariate and multivariate analysis for progression-free and overall survival

Total (N=171)	Events	Median PFS (months)	p-uni	HR [95%CI]	p-multi
DLBCL/HGBCL	75	6	0.59	-	-
PMBCL/TFL	19	7
Age > 60 years	43	6	0.91	-	-
<= 60 years	51	5
Male	68	5	0.42	-	-
Female	26	8
ECOG PS 2–4	15	3	0.02	0.8 [0.4–1.4]	0.36
0–1	79	7
IPI score 3–5	64	3	<0.001	0.5 [0.3–0.8]	0.002
0–2	30	16
Previous therapies > 2	78	5	0.11	-	-
2	16	14
Bridging therapy: yes	52	4	0.02	0.7 [0.5–1.1]	0.16
no	42	8
Refractory disease: yes	79	5	0.08	-	-
no	15	26
DLIx: low	35	3	0.02	0.6 [0.4–0.9]	0.04
high	81	9
Total (N=171)	Events	Median OS (months)	p-uni	HR [95%CI]	p-multi
DLBCL/HGBCL	45	16	0.63	-	-
PMBCL/TFL	11	18
Age > 60 years	29	16	0.30	-	-
<= 60 years	27	18
Male	39	17	0.77	-	-
Female	17	17
ECOG PS 2–4	10	8	0.03	0.8 [0.4–1.5]	0.43
0–1	46	18
IPI score 3–5	44	14	<0.001	0.3 [0.2–0.6]	0.01
0–2	12	22
Previous therapies > 2	47	17	0.19	-	-
2	9	17
Bridging therapy: yes	30	15	0.20	-	-
no	36	18
Refractory disease: yes	49	16	0.07	-	-
no	7	27
DLIx: low	29	7	0.02	0.5 [0.3–0.9]	0.02
high	65	26

DLIx, delta lymphocyte index; HR, hazard ratio; CI, confidence interval; uni, univariate; multi, multivariate; DLBCL, diffuse large B-cell lymphoma; HGBCL, high grade B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma; ECOG, European Cooperative Oncology Group; PS, performance status; IPI, international prognostic index